Les anunciamos el lanzamiento de la 9ª convocatoria de IMI2, que incluye los siguientes topics:

• Addressing the clinical burden of Clostridium difficile infection (CDI): evaluation of the burden, current practices and set up of a European research platform (part of the IMI New Drugs for Bad Bugs (ND4BB) programme)
• Development of immune tolerance therapies for the treatment of rheumatic diseases
• Data quality in preclinical research and development
• Next generation of electronic translational safety – NEXGETS
• Identification and validation of non-invasive markers across the spectrum of nonalcoholic fatty liver disease (NAFLD)
• Joint influenza vaccine effectiveness surveillance studies

Call 9

Fecha de cierre primera etapa: martes 26 de julio de 2016